AA
ALPS Advisors Portfolio holdings
AUM
$17.3B
1-Year Return
13.43%
This Quarter Return
+1.29%
1 Year Return
+13.43%
3 Year Return
+69.62%
5 Year Return
+161.48%
10 Year Return
+94.79%
AUM
$8.89B
AUM Growth
-$1.49B
(-14%)
Cap. Flow
-$1.59B
Cap. Flow
% of AUM
-17.93%
Top 10 Holdings %
Top 10 Hldgs %
47.67%
Holding
1,012
New
106
Increased
478
Reduced
302
Closed
124
Top Buys
| 1 |
Energy Transfer Partners
ET
|
+$33.8M |
| 2 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$30.5M |
| 3 |
Newmont
NEM
|
+$30M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$29.6M |
| 5 |
Conagra Brands
CAG
|
+$24.9M |
Top Sells
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$430M |
| 2 |
JPMorgan Chase
JPM
|
+$162M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$132M |
| 4 |
Pfizer
PFE
|
+$111M |
| 5 |
Yum! Brands
YUM
|
+$105M |
Sector Composition
| 1 | Energy | 59.33% |
| 2 | Technology | 6.01% |
| 3 | Healthcare | 4.63% |
| 4 | Consumer Discretionary | 3.72% |
| 5 | Financials | 3.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RXDX
301
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $1.78M | 0.02% |
+45,064
| New | +$1.78M |
|
302
Enanta Pharmaceuticals
ENTA
$189M
| $1.76M | 0.02% |
23,521
-1,250
| -5% | -$93.5K |
|
303
Immunocore
IMCR
$1.83B
| $1.74M | 0.02% |
50,670
-2,993
| -6% | -$102K |
|
|
304
JPMorgan Chase
JPM
$820B
| $1.73M | 0.02% |
10,940
-1,022,895
| -99% | -$162M |
|
|
MYOV
305
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.68M | 0.02% |
+107,982
| New | +$1.68M |
|
306
Rocket Pharmaceuticals
RCKT
$340M
| $1.63M | 0.02% |
74,577
-3,393
| -4% | -$74.1K |
|
307
Northrop Grumman
NOC
$82.1B
| $1.62M | 0.02% |
4,194
-1,369
| -25% | -$530K |
|
308
Regenxbio
RGNX
$476M
| $1.62M | 0.02% |
49,491
-2,721
| -5% | -$89K |
|
309
Atara Biotherapeutics
ATRA
$83.4M
| $1.61M | 0.02% |
4,093
-62
| -1% | -$24.4K |
|
310
Iron Mountain
IRM
$27.6B
| $1.61M | 0.02% |
30,824
-2,594
| -8% | -$136K |
|
311
Organogenesis Holdings
ORGO
$614M
| $1.61M | 0.02% |
174,336
-8,215
| -5% | -$75.9K |
|
|
AAT
312
American Assets Trust
AAT
$1.25B
| $1.61M | 0.02% |
42,810
+18,184
| +74% | +$683K |
|
313
Merus
MRUS
$5.01B
| $1.59M | 0.02% |
+50,050
| New | +$1.59M |
|
314
Keros Therapeutics
KROS
$630M
| $1.58M | 0.02% |
27,071
-1,528
| -5% | -$89.4K |
|
315
StepStone Group
STEP
$4.83B
| $1.58M | 0.02% |
38,000
-1,000
| -3% | -$41.6K |
|
316
Crinetics Pharmaceuticals
CRNX
$3.42B
| $1.56M | 0.02% |
54,964
+7,528
| +16% | +$214K |
|
317
Anavex Life Sciences
AVXL
$850M
| $1.53M | 0.02% |
+87,972
| New | +$1.53M |
|
318
FibroGen
FGEN
$45.4M
| $1.51M | 0.02% |
4,292
-249
| -5% | -$87.8K |
|
319
Hess Midstream
HESM
$5.29B
| $1.5M | 0.02% |
54,199
+29,092
| +116% | +$804K |
|
320
Advanced Micro Devices
AMD
$249B
| $1.5M | 0.02% |
10,396
-13,056
| -56% | -$1.88M |
|
321
McEwen Inc.
MUX
$729M
| $1.49M | 0.02% |
168,427
-7,389
| -4% | -$65.5K |
|
322
Replimune Group
REPL
$455M
| $1.47M | 0.02% |
54,269
-3,053
| -5% | -$82.8K |
|
323
Zoetis
ZTS
$66.9B
| $1.46M | 0.02% |
5,976
-9,045
| -60% | -$2.21M |
|
324
Coherus Oncology, Inc. Common Stock
CHRS
$157M
| $1.42M | 0.02% |
88,859
-4,873
| -5% | -$77.8K |
|
|
BDN
325
Brandywine Realty Trust
BDN
$757M
| $1.37M | 0.02% |
101,762
-4,600
| -4% | -$61.7K |
|